Developing stable, long-acting injectable (LAI) drugs remains one of the most demanding frontiers in pharmaceutical science. These formulations are critical for improving patient compliance, reducing dosing frequency, and ensuring consistent therapeutic effects, particularly for chronic conditions such as schizophrenia, HIV, and hormone-sensitive cancers. Recent innovations in materials science, nanotechnology, and prodrug design have opened new avenues for creating more effective and reliable long-acting injectables, addressing long-standing challenges in stability, release kinetics, and manufacturing scalability.

Nanotechnology in Drug Delivery

Nanotechnology has revolutionized the design of long-acting injectables by enabling precise control over drug encapsulation, protection, and release. Drug particles engineered at the nanometer scale exhibit enhanced stability due to increased surface area to volume ratios and improved solubility for poorly water-soluble compounds. Nanoparticles can encapsulate active pharmaceutical ingredients (APIs) within biocompatible matrices, shielding them from enzymatic degradation and premature clearance by the immune system.

Types of Nanocarriers

Several nanocarrier platforms are currently being explored for LAI formulations:

  • Lipid-based nanoparticles: Solid lipid nanoparticles and nanostructured lipid carriers offer high drug loading for lipophilic drugs and can be designed for sustained release over weeks. For example, long-acting injectable antipsychotics like aripiprazole lauroxil utilize lipid-based prodrug approaches that form nanoparticles in situ after injection.
  • Polymeric nanoparticles: These are typically composed of biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) or polycaprolactone. They release the drug through diffusion and polymer erosion, offering predictable release profiles. Recent advances include the use of block copolymer nanoparticles with tunable degradation rates that enable release durations of up to six months.
  • Liposomes: While traditionally used for intravenous delivery, multilamellar liposomes have been adapted for intramuscular or subcutaneous injection. They can encapsulate both hydrophilic and hydrophobic drugs and release them slowly as the lipid bilayers degrade.

Nanotechnology also addresses bioavailability issues common with many antiretroviral drugs. For instance, long-acting injectable formulations of cabotegravir and rilpivirine (Cabenuva) leverage nanoparticle suspensions to maintain therapeutic plasma levels for months, reducing the dosing frequency from daily to monthly or even bimonthly. The key advantage is the reduction of peak-to-trough fluctuations, minimizing side effects and improving patient outcomes.

Use of Biodegradable Polymers

Biodegradable polymers form the backbone of many commercial LAI systems. These materials must be biocompatible, non-immunogenic, and capable of degrading into harmless byproducts that are easily eliminated from the body. PLGA is the most widely used polymer, approved by regulatory agencies for various drug delivery applications. Its degradation rate can be tailored by varying the ratio of lactic acid to glycolic acid, molecular weight, and end-group functionality.

Mechanisms of Controlled Release

Drug release from polymer-based LAI systems follows three phases: an initial burst release of surface-adsorbed drug, a sustained release phase governed by polymer degradation and drug diffusion, and a final erosion phase as the polymer matrix disintegrates. Innovations in polymer chemistry have enabled more precise control over these phases. For example, encapsulation of peptides and proteins within PLGA microspheres—such as leuprolide acetate (Lupron Depot)—provides consistent release for up to six months for hormone therapy in prostate cancer.

Recent advances include the development of block copolymers of PLGA with polyethylene glycol (PEG), which reduce initial burst release and extend release duration. Another promising area is the use of polyester-polyether blends that form hydrogels upon injection, creating a depot that slowly releases the drug over time. These blends also minimize the need for organic solvents during manufacturing, improving the safety profile of the formulation.

Researchers are also exploring non-linear polymer architectures, such as branched PLGA, which offer higher drug loading and more consistent release compared to linear polymers. Additionally, the incorporation of nanoscale fillers like hydroxyapatite can modulate the degradation environment and prolong release for bone-targeting applications.

Prodrug Strategies

Prodrug approaches involve chemical modification of the active drug to create an inactive precursor that converts enzymatically or chemically into the parent compound after injection. This strategy enhances the stability of the drug in the injection depot, reduces systemic exposure, and extends the release period. The conversion rate can be engineered by selecting appropriate linker moieties that are cleaved at a controlled rate by esterases or phosphatases present in the physiological milieu.

Examples of Prodrug-Based LAIs

One prominent example is aripiprazole lauroxil (Aristada), which is a prodrug of aripiprazole. After intramuscular injection, the prodrug forms a depot that slowly releases the active molecule through hydrolysis. This formulation provides sustained therapeutic levels for up to two months with a single injection. Clinical studies have demonstrated improved relapse prevention and adherence compared to oral formulations, with a tolerability profile similar to the parent drug.

Another notable prodrug LAI is octreotide pamoate (Sandostatin LAR), used for acromegaly and neuroendocrine tumors. The prodrug is encapsulated within PLGA microspheres, releasing octreotide over four weeks. Innovations in prodrug design have recently focused on dendrimeric prodrugs and antibody-targeted prodrugs that can deliver the drug to specific tissues, reducing off-target effects. For example, a long-acting injectable prodrug of buprenorphine (CAM2038) uses a lipid-based formulation that forms a gel depot, providing weekly or monthly release for opioid use disorder treatment.

The main challenge with prodrug strategies is predicting conversion rates in vivo, which can vary significantly between patients. Researchers are using physiologically based pharmacokinetic (PBPK) modeling to better predict prodrug conversion and release profiles, enabling personalized dosing regimens.

Advanced Formulation Techniques

Emerging formulation techniques are expanding the toolkit for designing long-acting injectables beyond traditional microspheres and nanoparticles. These include in situ forming gels, implantable devices, and stimuli-responsive systems that release drugs in response to specific biological cues.

In Situ Forming Gels and Implants

In situ forming depot systems consist of a drug-polymer solution that is injected as a liquid and solidifies at the injection site. For example, subcutaneous injection of a PLGA solution in a biocompatible solvent (e.g., N-methyl-2-pyrrolidone) rapidly forms a gel depot due to solvent exchange with physiological fluids. Systems like Eligard (leuprolide acetate) use this approach, providing sustained release for up to six months for prostate cancer. Recent innovations include thermosensitive hydrogels that gel at body temperature, such as those based on chitosan-glycerol phosphate or poly(N-isopropylacrylamide) copolymers.

Implantable devices, such as the Propel mini-endoprosthesis used for sinus surgery, are being adapted for systemic long-acting drug delivery. These devices are made from biodegradable polymers and can be loaded with high drug doses. Advances in 3D printing enable the fabrication of patient-specific implants with complex internal geometries that control drug release. For instance, 3D-printed PLGA implants loaded with antiretroviral drugs have shown promise for pre-exposure prophylaxis (PrEP) in preclinical models.

Stimuli-Responsive Systems

Stimuli-responsive LAI formulations release drugs only when triggered by specific endogenous or exogenous signals. pH-sensitive polymers, for example, can release drug in acidic microenvironments such as tumors or inflamed tissues. Enzyme-responsive systems cleave linkers in the presence of overexpressed enzymes like matrix metalloproteinases (MMPs) in cancer or arthritis. Exogenous triggers like ultrasound or near-infrared light are also being explored for on-demand release. A recent study demonstrated that ultrasound-responsive PLGA microcapsules could provide pulsatile release of insulin over three months in a diabetic rat model.

Challenges and Future Directions

Despite significant progress, several challenges remain in formulating stable, long-acting injectables. Burst release—an initial rapid release of a large drug fraction—can lead to toxicity or reduced duration of action. Strategies to mitigate burst release include coating nanoparticles with PEG, using core-shell architectures, or optimizing the polymer-to-drug ratio. Sterile manufacturing is another major hurdle, as LAI formulations often require aseptic processing to avoid microbial contamination. The complexity of these systems increases the risk of particulate matter formation or drug degradation during sterilization.

Immunogenicity is a growing concern, particularly for protein-based therapeutics. Even biodegradable polymers can trigger foreign body reactions, leading to encapsulation by fibrous tissue and premature drug release. Researchers are developing coatings with immunomodulatory agents to suppress localized inflammation. Additionally, the formulation must remain stable during long-term storage—often up to 24 months—without significant aggregation or chemical degradation. Lyophilization and advanced drying techniques are being optimized for heat-sensitive drugs.

Future Directions

The future of long-acting injectables lies in multifunctional formulations that combine drug release with imaging capabilities for real-time monitoring. Integrating contrast agents into LAI systems could allow clinicians to track depot formation and erosion using MRI or CT. Advances in artificial intelligence are enabling high-throughput screening of polymer-drug combinations to predict release profiles and stability. Furthermore, personalized LAI formulations tailored to an individual’s metabolism and disease state could enhance therapeutic outcomes.

Shared manufacturing platforms that standardize equipment and processes for LAI production are being developed to reduce costs and accelerate clinical translation. The expansion of LAI technologies into new therapeutic areas, such as vaccines (e.g., long-acting injectable mRNA vaccines) and antimalarials, holds great promise for global health. Regulatory agencies are also updating guidance documents to facilitate the approval of innovative LAI products, emphasizing the need for robust in vitro-in vivo correlation models. As these innovations converge, long-acting injectables will become a cornerstone of modern medicine, offering patients freedom from frequent dosing and improving adherence across a broad range of chronic and life-threatening conditions.